Zacks
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?
📈
AI Sentiment
Highly Positive
9/10
- Home
- ADCT
ADCT
ADC Therapeutics SA
as of 12-17-2025 3:36pm EST
$3.71
$0.26
-6.55%
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Chart Type:
Time Range:
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 496.7M | IPO Year: | 2020 |
| Target Price: | $7.60 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $4.80 | Next Earning Date: | 11-10-2025 |
| Revenue: | $75,209,000 | Revenue Growth: | 6.35% |
| Revenue Growth (this year): | 10.36% | Revenue Growth (next year): | 3.87% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
Compare ADCT vs Leading Stocks
See how ADCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.